UBS Downgrades Chemours to Neutral, Lowers Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Joshua Spector downgraded Chemours (NYSE:CC) from Buy to Neutral and reduced the price target from $37 to $21, indicating a more cautious outlook on the company.

March 05, 2024 | 10:58 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Chemours was downgraded by UBS from Buy to Neutral with a significant reduction in price target from $37 to $21.
The downgrade from Buy to Neutral by a major analyst such as UBS, coupled with a significant reduction in the price target, suggests a more cautious or negative outlook on Chemours. This is likely to influence investor sentiment negatively in the short term, potentially leading to a decrease in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100